AI-ACCELERATED DRUG DISCOVERY
Advancing AI in Drug Discovery at Key Oncology and Biotech Conferences
Chicago, IL & San Diego, CA – Receptor.AI, a pioneering drug discovery startup specializing in AI-driven drug discovery, recently showcased its groundbreaking advancements at two significant industry gatherings: the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago and the BIO International Convention in San Diego.
From May 31 to June 4, the ASCO 2024 Annual Meeting hosted approximately 50,000 participants from across the globe, making it one of the largest gatherings in oncology. Receptor.AI took this opportunity to engage with leading minds in cancer research and treatment.
Our CEO, Dr. Alan Nafiiev, engaged extensively with oncology professionals, sharing insights and exploring the latest in AI-driven drug discovery. The discussions and connections made at ASCO 2024 have reinforced our commitment to advancing cancer research, with an emphasis on applying artificial intelligence to develop new therapeutic strategies.
Following the success at ASCO, Receptor.AI continued its impactful presence at the BIO International Convention held from June 3-6 in San Diego. The conference brought together industry professionals to discuss the latest trends and innovations in drug discovery.
On behalf of Receptor.AI, Dr. Alan Nafiiev showcased our innovative AI model for predicting Protein-Protein Interactions (PPI) using a template-agnostic approach. This model demonstrates superior performance, especially in scenarios where structural templates of the complexes are absent—a challenge that previous technologies, including AlphaFold3, could not overcome.
The launch of our model at BIO 2024 was met with enthusiastic responses, highlighting the readiness within the industry for innovative solutions that can enhance current drug discovery pipelines. This has paved the way for several new projects focused on leveraging our capabilities in PPIs, anticipated to significantly impact preclinical drug development.
You can learn more about our new PPI workflow via the link.
These back-to-back conferences have not only solidified the position of Receptor.AI as a leader amongst AI biotech companies but have also sparked numerous opportunities for collaboration and innovation in drug discovery. The insights gained and the connections made are invaluable as we continue to drive progress in the AI-driven drug discovery design.
"We are incredibly grateful for the warm reception and the engaging discussions we’ve had at both ASCO and BIO," said Dr. Nafiiev. "These interactions inspire our team to continue developing AI solutions that could one day transform how we approach complex diseases by advancing our understanding and application of artificial intelligence in drug discovery."
Receptor.AI looks forward to continuing this momentum at future events and further engaging with the biotech community to share our latest developments.
Stay tuned for more updates as we launch these exciting projects and continue our journey towards revolutionizing the landscape of AI drug discovery.
